Chengdu,China, April 17th, 2017, HitGen Ltd. is pleased to announce that the companyhas entered into a multi-year research collaboration and license agreement with Pfizer Inc. (NYSE: PFE) to build and screen novelDNA-encoded libraries (DELs) in order to potentially discover unique smallmolecule leads to be used in drug development. Through the collaboration, HitGen and Pfizer scientists will applyHitGen’s advanced technology platform and research capabilities in the design,synthesis, and screening of multiple proprietary DELs for Pfizer’s drugdiscovery efforts. In addition, HitGen will screen their own DELs, consistingof billions of compounds, against a selected number of Pfizer’s therapeutictargets. Novel lead compounds from the HitGen DELs willbe licensed exclusivelyto Pfizer for furtherresearch and development. Pfizer will fund the research at HitGen.
“We are delighted to announce this major collaborationwith Pfizer, one of the leading multi-national biopharmaceutical companies inthe world. We will work closely with Pfizer scientists to build proprietary DELs to supportthe discovery of a generation of new medicines to address unmet medical needs. Thiscollaboration reflects HitGen’s capabilities, expertise, and flexibility todevelop business models to meet the needs of our collaboration partners,” said Dr. Jin Li, Chairman of the Board and Chief Executive Officer of HitGen.
“We are excited about our new collaboration withHitGen” said Dr. Tony Wood, Senior Vice President and Head of Medicinal Sciences,Pfizer. “We look forward to identifying new opportunities that will furtherexpand our ability to identify new leads for multiple target families. The generationof proprietary DELs will leverage Pfizer’s parallel medicinal chemistryexpertise and potentially accelerate the path of new medicines from idea to theclinic.”
About Pfizer Inc. - Working together for ahealthier world®
At Pfizer, weapply science and our global resources to bring therapies to people that extendand significantly improve their lives. We strive to set the standard forquality, safety and value in the discovery, development and manufacture ofhealth care products. Our global portfolio includes medicines and vaccines aswell as many of the world's best-known consumer health care products. Everyday, Pfizer colleagues work across developed and emerging markets to advancewellness, prevention, treatments and cures that challenge the most feareddiseases of our time. Consistent with our responsibility as one of the world'spremier innovative biopharmaceutical companies, we collaborate with health careproviders, governments and local communities to support and expand access toreliable, affordable health care around the world. For more than 150 years,Pfizer has worked to make a difference for all who rely on us. For moreinformation, please visit us at www.pfizer.com. In addition, to learn more,follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like uson Facebookat Facebook.com/Pfizer.
Pfizer Disclosure Notice:
Theinformation contained in this release is as of April 17th, 2017.Pfizer assumes no obligation to update forward-looking statements contained in thisrelease as the result of new information or future events or developments.
About HitGen Ltd.
HitGen is an innovation driven lifescience company with headquarters and main research facilities based in Chengdu, China and withlaboratories in Houston, Texas， USA. HitGenhas established a unique platform for drug discovery research. Our DNA encoded chemical libraries (DELs) contain more than 20 billion novel,diverse, drug-like compounds. These compounds are members of DELssynthesised from many hundreds of distinct chemicalscaffolds, designed with tractable chemistry based on proven results for identifyingdrug leads against targets from both known and novel protein classes. HitGen is collaborating with multiplepharmaceutical and biotech companies, and academic research institutes todiscover and develop the therapeutics of the future.
For further information, pleasecontact
Dr. Jin Li, Chairman & CEO， HitGen Ltd. Tel: +86 28 85197385
Dr. Barry Morgan, Chief ScientificOfficer，HitGen Ltd. Tel: +1 5088409646
